TAIPEI, Taiwan – One of the more interesting questions in biopharma today is the direction in which the biosimilars market is headed. Speaking at the recent BioBusiness Asia Conference, part of BioTaiwan 2017, industry insiders shared their views on the outlook for this market, highlighting the state of flux and uncertainty that still defines the segment.